EGFR amplification, which was reported in 19–29% of osimertinib-resistant NSCLC patients [21,34], may drive the resistance process by aberrant activation of several downstream signalling pathways such as RAS/RAF/MAPK, PI3K/AKT/mTOR and STAT [34]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.